2020
Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck
Jacobs D, Olino K, Park HS, Clune J, Cheraghlou S, Girardi M, Burtness B, Kluger H, Judson BL. Primary Treatment Selection for Clinically Node-Negative Merkel Cell Carcinoma of the Head and Neck. Otolaryngology 2020, 164: 1214-1221. PMID: 33079010, DOI: 10.1177/0194599820967001.Peer-Reviewed Original ResearchConceptsNode-negative Merkel cell carcinomaLymph node evaluationImproved overall survivalPrimary tumor excisionMerkel cell carcinomaCase volumeOverall survivalSurgical managementCell carcinomaTumor excisionTreatment selectionNode evaluationCox proportional hazards regressionGuideline-recommended carePrimary treatment selectionNational Cancer DatabaseNode-negative diseasePercentage of patientsRetrospective cohort analysisInitial surgical managementKaplan-Meier analysisWide local excisionProportional hazards regressionRates of receiptInitial management
2017
Double‐blind, randomized phase 3 trial of low‐dose 13‐cis retinoic acid in the prevention of second primaries in head and neck cancer: Long‐term follow‐up of a trial of the Eastern Cooperative Oncology Group‐ACRIN Cancer Research Group (C0590)
Bhatia AK, Lee J, Pinto HA, Jacobs CD, Limburg PJ, Rubin P, Arusell RM, Dunphy EP, Khandekar JD, Reiner SA, Baez‐Diaz L, Celano P, Li S, Li Y, Burtness BA, Adams GL, Pandya KJ. Double‐blind, randomized phase 3 trial of low‐dose 13‐cis retinoic acid in the prevention of second primaries in head and neck cancer: Long‐term follow‐up of a trial of the Eastern Cooperative Oncology Group‐ACRIN Cancer Research Group (C0590). Cancer 2017, 123: 4653-4662. PMID: 28786105, PMCID: PMC5693641, DOI: 10.1002/cncr.30920.Peer-Reviewed Original ResearchConceptsSecond primary tumorsOverall survivalFormer smokersDevelopment of SPTsIncidence of SPTsEarly-stage SCCHNFuture prevention trialsImproved overall survivalClinical risk factorsSquamous cell cancerLog-rank testLong-term resultsPotential survival advantageCompeting-risk approachCumulative incidenceIndex tumorCell cancerPrevention trialsPrimary tumorRisk factorsSubset analysisDry skinSurvival advantagePatientsTargeted interventionsTreatment guidelines and patterns of care in oral cavity squamous cell carcinoma: Primary surgical resection vs. nonsurgical treatment
Fujiwara RJT, Burtness B, Husain ZA, Judson BL, Bhatia A, Sasaki CT, Yarbrough WG, Mehra S. Treatment guidelines and patterns of care in oral cavity squamous cell carcinoma: Primary surgical resection vs. nonsurgical treatment. Oral Oncology 2017, 71: 129-137. PMID: 28688680, DOI: 10.1016/j.oraloncology.2017.06.013.Peer-Reviewed Original ResearchConceptsOral cavity squamous cell carcinomaNational Cancer Data BaseLate-stage diseasePrimary nonsurgical treatmentOral cavity malignancyNonsurgical treatmentSquamous cell carcinomaOverall survivalSurgical resectionCell carcinomaTreatment modalitiesNational Comprehensive Cancer Network Clinical Practice GuidelinesAcademic/research programMultimodality clinical trialsDefinitive radiation therapyImproved overall survivalDecreased overall survivalPrimary surgical resectionOral cavity cancerNon-randomized natureClinical practice guidelinesPatterns of careNon-white raceProportional hazards modelBinary logistic regressionHypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer: Patterns of Care and Survival
Bledsoe TJ, Park HS, Stahl JM, Yarbrough WG, Burtness BA, Decker RH, Husain ZA. Hypofractionated Radiotherapy for Patients with Early-Stage Glottic Cancer: Patterns of Care and Survival. Journal Of The National Cancer Institute 2017, 109: djx042. PMID: 28521361, DOI: 10.1093/jnci/djx042.Peer-Reviewed Original ResearchConceptsEarly-stage glottic cancerOverall survivalGlottic cancerMultivariable Cox proportional hazards regressionNational Comprehensive Cancer Network guidelinesNational Cancer Data BaseCox proportional hazards regressionPropensity scoreClinical T1 diseaseImproved overall survivalHigh-volume centersProportional hazards regressionLog-rank testPatterns of careRadiation treatment schedulesLarge national databaseCT2 diseaseDefinitive radiotherapyT1 diseaseHypofractionated radiotherapyImproved survivalMultivariable analysisTreatment patternsHazards regressionNetwork guidelines
2014
Trends and variations in the use of adjuvant therapy for patients with head and neck cancer
Chen MM, Roman SA, Yarbrough WG, Burtness BA, Sosa JA, Judson BL. Trends and variations in the use of adjuvant therapy for patients with head and neck cancer. Cancer 2014, 120: 3353-3360. PMID: 25042524, DOI: 10.1002/cncr.28870.Peer-Reviewed Original ResearchConceptsAdjuvant therapyAdverse pathologic featuresAdjuvant chemoradiationPathologic featuresNeck cancerNational Comprehensive Cancer Network guidelinesNational Cancer Data BaseMedicare/Medicaid insuranceImproved overall survivalHospital-level factorsCox multivariate regressionLog-rank testMultivariate logistic regressionForm of radiotherapyQuality of careAdjuvant radiotherapyOverall survivalMedicaid insuranceNetwork guidelinesCancer CenterLaryngeal cancerPractice patternsChemoradiationOral cavityPatients
2010
Defining Venous Involvement in Borderline Resectable Pancreatic Cancer
Chun YS, Milestone BN, Watson JC, Cohen SJ, Burtness B, Engstrom PF, Haluszka O, Tokar JL, Hall MJ, Denlinger CS, Astsaturov I, Hoffman JP. Defining Venous Involvement in Borderline Resectable Pancreatic Cancer. Annals Of Surgical Oncology 2010, 17: 2832-2838. PMID: 20725860, DOI: 10.1245/s10434-010-1284-9.Peer-Reviewed Original ResearchConceptsR0 resection ratePreoperative therapyPreoperative chemoradiationResection ratePancreatic adenocarcinomaVenous involvementBilateral narrowingUnilateral narrowingSurvival rateBorderline resectable pancreatic adenocarcinomaBorderline resectable pancreatic cancerMargin-negative resection rateMedian overall survival rateHigher R0 resection rateImproved overall survivalResectable pancreatic cancerNegative lymph nodesMargin-negative resectionOverall survival rateResectable pancreatic adenocarcinomaSuperior mesenteric veinPreoperative computed tomographyType IIBackgroundPancreatic adenocarcinomaBorderline resectability